The Effect of AMP Human Sodium Bicarbonate Lotion on Hydration (AMPlify Human Hydration Study)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Fluid Retention - Change in Expelled Urine Volume
研究概览
简要总结
The purpose of this research study is to evaluate the effects of a topical sodium bicarbonate lotion on physiological and psychological responses associated with hydration status and fluid balance in humans during passive heat stress. Currently, the ingestion of sodium has been an effective measure for improvements in fluid regulation and hydration status in humans. However, the investigators do not know its regulatory relationship with measurements of fluid balance when supplemented through the skin.
详细描述
Design This laboratory study is a randomized, counterbalanced, crossover design involving 20 participants (20 males) from the local community and university. This project will be conducted within the thermal physiology laboratory, complete with a climatic chamber (Cantrol, CES +13/+44) located within the Human Performance Laboratory (HPL) at the University of Connecticut. The investigators expect each interested individual will complete both phases included within the study design within a randomized, counterbalanced order.
Participant grouping orders will be randomly assigned by the project's lead student investigator (Jeb Struder). Each phase will be fairly similar in procedures completed; however, one phase will be completed with a trial that introduces a biomedical intervention (sodium bicarbonate topical lotion; PR group), while the other phase will be completed with a trial that introduces a placebo (PLA group) product similar to the biomedical intervention. Approximately 24 hours should pass between the completion of each session within a phase of the study. Additionally, approximately 3 days should pass between the completion of a phase and the initiation of the next phase (5th session completed).
Environmental Conditions Sessions I, II, and III of both counterbalanced groups (PR and PLA) will all be completed within thermoneutral conditions. Session IV of both counterbalanced groups (PR and PLA) will be conducted within the climatic chamber set to a climate with ambient temperature at approximately 33C (91.4F) and relative humidity at approximately 25%.
Baseline Assessments (PR/PLAI, PR/PLAII, PR/PLA III) Baseline visits should be completed over 3 consecutive days for the establishment of baseline measurements regarding the participant's body weight, dietary behaviors, and hydration status. Each assessment will be performed at the relatively same time of day (early to late morning) and will involve approximately 30 minutes spent within the laboratory space of the Human Performance Laboratory (HPL). All Baseline Assessment sessions will consist of fairly similar data collection procedures and will begin with the participant providing the completed 24-h dietary recall log, thirst perception scale, and filled urine jug to the administrating researcher. Additionally, the participant will be asked to provide a morning urine sample and nude body weight for the assessment of session-specific hydration status and Fluid Retention Index (FRI). Furthermore, once these tasks are completed, an HPL trained researcher will conduct a blood draw for the collection of approximately ½ teaspoon of blood. Each session will deviate slightly in additional tasks required for completion.
Day 1 (PR/PLAI): After the collection of a morning urine sample and nude body weight measurement, the participant's height (for additional anthropometrics) and resting blood pressure (for safety precautions) will be measured. Additionally, after the completion of the blood draw, the final task for this session will be the participant's familiarization to the Cognitive/Perceptual Battery tasks that you will be tested during Session 4 (PR/PLAIV).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 35 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Males within the age range of 18-35 years old.
- •Individuals who are classified as recreationally active individuals: physical activity performed ≥3 days per week with sessions lasting ≥30 minutes in duration.
- •Individuals who have been medically cleared for participation in this study by the medical safety monitor.
排除标准
- •Cannot understand English (written and/or verbally communicated).
- •Hearing impaired to where verbal communications cannot be understood and/or followed safely.
- •Individuals who self-report history of complications with psychological disorders or chronic illness (eating disorders, cardiovascular, kidney, liver, metabolic, neuromuscular, pulmonary, and/or sickle cell disease).
- •Individuals who have chronic health problems that may affect the participant's ability to thermoregulate or sweat normally.
- •Individuals who have a history of exertional heat illness within the past 3 years.
- •Individuals who are taking any prescription or non-prescription medication(s) that may specifically impact cardiometabolic, pulmonary, renal, and/or thermoregulatory function (i.e. amphetamines, antihypertensives, anticholinergics, acetaminophen, NSAIDs, aspirin, and water pills).
- •Individuals who have consumed more than (>3,500 mg) or less than (<2,300 mg) the average amount of sodium consumed per day at time of testing.
- •Individuals who have consumed more than (>1.8L) or less than (<0.8L) the average amount of fluids consumed per day at time of testing.
- •Individuals classified as hypertensive while at rest (SBP: ≥140 mmHg and/or DBP: ≥90 mmHg; will be measured during first visit).
- •Individuals who have not abstained from use of supplements that may affect/enhance hydration status (i.e. creatine, sodium bicarbonate, potassium, magnesium, dandelion, vitamin B6, other natural diuretics) at time of testing.
- •Individuals who report they are suffering from a fever or current illness at time of testing.
- •Individuals who are suffering from a current musculoskeletal injury that limits the participant's ability to walk, stand, and/or sit upright in a chair for long periods of time.
- •Individuals who have an active lesion at the location of topical solution application.
- •Individuals how are allergic/sensitive to ingredients within the study-specific Topical Lotions: (Menthol [0.5%], sodium bicarbonate (baking soda), water, isopropyl palmitate, lecithin, poloxamer 407, cetyl alcohol, propylene glycol, denatured alcohol, benzyl alcohol, polyglyceryl-4 laurate, sodium hydroxide, sodium lauryl sulfate, sorbic acid, and fragrance).
- •Individuals who are allergic/sensitive to iodine, water-based ultrasound solution, and/or medical tape.
- •Individuals who have experienced any recent major life events (i.e. death in family, divorce, wedding) in the previous 6 months.
- •Individuals who have donated blood within the previous month.
- •Individuals who have an implanted pacemaker or internal defibrillator.
- •Individuals who use tobacco products (including smoking cessation products).
研究组 & 干预措施
PR Lotion Topical Solution
Approximately 50 grams of PR Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. This lotion will be applied once during the 4th of session of their PR Lotion Phase and will remain on the skin for approximately 4.5 hours.
干预措施: PR Lotion - AMP Human Performance (Other)
Placebo Lotion Topical Solution
Approximately 50 grams of the Placebo Lotion will be applied by the participants to their upper extremities (arms) in addition to their neck, upper back, chest, and midsection if necessary. The only difference in ingredients for this Placebo Lotion will be the exclusion of the sodium bicarbonate ingredient. This lotion will be applied once during the 4th of session of their Placebo Lotion Phase and will remain on the skin for approximately 4.5 hours.
干预措施: Placebo Lotion (Other)
结局指标
主要结局
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of fluid retention via collection of urine volume
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the 180 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Fluid Retention - Change in Expelled Urine Volume
时间窗: Hydration Baseline Day 1
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Hydration Baseline Day 2
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Hydration Baseline Day 3
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 30 minute mark.
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 90 minute mark.
Assessment of fluid retention via collection of urine volume
Fluid Retention - Change in Expelled Urine Volume
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of fluid retention via collection of urine volume
Kidney Function - Change in Aldosterone Response
时间窗: Hydration Baseline Day 1
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Hydration Baseline Day 2
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Hydration Baseline Day 3
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the -30 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Aldosterone Response
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Hydration Baseline Day 1
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Hydration Baseline Day 2
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Hydration Baseline Day 3
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the -30 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Copeptin Response
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of blood biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Hydration Baseline Day 1
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Hydration Baseline Day 2
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Hydration Baseline Day 3
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Kidney Function - Change in Creatinine Response
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of kidney function in regards to fluid retention via assessment of urine biomarkers associated with kidney function
Change in Whole Blood Sodium Levels
时间窗: Hydration Baseline Day 1
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Hydration Baseline Day 2
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Hydration Baseline Day 3
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the -75 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the -60 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the -30 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Sodium Levels
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of fluid retention via whole blood sodium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Hydration Baseline Day 1
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Hydration Baseline Day 2
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Hydration Baseline Day 3
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the -75 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the -60 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the -30 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Potassium Levels
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of fluid retention via whole blood potassium (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Hydration Baseline Day 1
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Hydration Baseline Day 2
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Hydration Baseline Day 3
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the -90 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the -75 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the -60 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the -30 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the 0 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the 60 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
Change in Whole Blood Chloride Levels
时间窗: Intervention Trial (Day 4) at the 120 minute mark.
Assessment of fluid retention via whole blood chloride (electrolyte levels) through blood biomarkers
次要结局
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the 180 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the 180 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the 180 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 180 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 180 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 180 minute mark.)
- Cardiovascular Function - Change in Blood Pressure(Intervention Trial (Day 4) at the 150 minute mark.)
- Cardiovascular Function - Change in Heart Rate Variability(Intervention Trial (Day 4) at the 150 minute mark)
- Cardiovascular Function - Change in Resting Heart Rate(Intervention Trial (Day 4))
- Cognitive Differences - Changes in Go/No Go Assessment(Intervention Trial (Day 4) at the 180 minute mark.)
- Cognitive Differences - Changes in 2 Choice Reaction Time(Intervention Trial (Day 4) at the 180 minute mark.)
- Cognitive Differences - Changes in Procedural Reaction Time(Intervention Trial (Day 4) at the 180 minute mark.)
- Cognitive Differences - Changes in Stroop Test(Intervention Trial (Day 4) at the 180 minute mark.)
- Perceptual Differences - Changes in Environmental Symptoms Questionnaire(Intervention Trial (Day 4) at the 180 minute mark.)
- Perceptual Differences - Changes in Fatigue Scale(Intervention Trial (Day 4) at the 180 minute mark.)
- Perceptual Differences - Changes in Gastrointestinal Distress Scale(Intervention Trial (Day 4) at the 180 minute mark.)
- Perceptual Differences - Changes in Thermal Sensation Scale(Intervention Trial (Day 4) at the 180 minute mark.)
- Perceptual Differences - Changes in Thirst Perception Scale(Intervention Trial (Day 4) at the 180 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Hydration Baseline 1)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Hydration Baseline 2)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Hydration Baseline 3)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the -90 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the -75 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the -60 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the -30 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the 0 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the 60 minute mark.)
- Fluid Retention - Change in Whole Blood Hematocrit Levels(Intervention Trial (Day 4) at the 120 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Hydration Baseline Day 1)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Hydration Baseline Day 2)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Hydration Baseline Day 3)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the -90 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the -75 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the -60 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the -30 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the 0 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the 60 minute mark.)
- Fluid Retention - Change in Whole Blood Hemoglobin Levels(Intervention Trial (Day 4) at the 120 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Hydration Baseline Day 1)
- Fluid Retention - Change in Plasma Osmolality Shifts(Hydration Baseline Day 2)
- Fluid Retention - Change in Plasma Osmolality Shifts(Hydration Baseline Day 3)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the -90 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the -75 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the -60 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the -30 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the 0 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the 60 minute mark.)
- Fluid Retention - Change in Plasma Osmolality Shifts(Intervention Trial (Day 4) at the 120 minute mark.)
- Kidney Function - Change in Urine Color(Hydration Baseline Day 1)
- Kidney Function - Change in Urine Color(Hydration Baseline Day 2)
- Kidney Function - Change in Urine Color(Hydration Baseline Day 3)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the -90 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 0 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 30 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 60 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 90 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 120 minute mark.)
- Kidney Function - Change in Urine Color(Intervention Trial (Day 4) at the 150 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Hydration Baseline Day 1)
- Kidney Function - Change in Urine Specific Gravity(Hydration Baseline Day 2)
- Kidney Function - Change in Urine Specific Gravity(Hydration Baseline Day 3)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the -90 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 0 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 30 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 60 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 90 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 120 minute mark.)
- Kidney Function - Change in Urine Specific Gravity(Intervention Trial (Day 4) at the 150 minute mark.)
- Kidney Function - Change in Urine Osmolality(Hydration Baseline Day 1)
- Kidney Function - Change in Urine Osmolality(Hydration Baseline Day 2)
- Kidney Function - Change in Urine Osmolality(Hydration Baseline Day 3)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the -90 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 0 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 30 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 60 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 90 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 120 minute mark.)
- Kidney Function - Change in Urine Osmolality(Intervention Trial (Day 4) at the 150 minute mark.)
- Cardiovascular Function - Change in Blood Pressure(Hydration Baseline Day 1)
- Cardiovascular Function - Change in Blood Pressure(Intervention Trial (Day 4) at the -90 minute mark.)
- Cardiovascular Function - Change in Blood Pressure(Intervention Trial (Day 4) at the 0 minute mark.)
- Cardiovascular Function - Change in Blood Pressure(Intervention Trial (Day 4) at the 30 minute mark.)
- Cardiovascular Function - Change in Blood Pressure(Intervention Trial (Day 4) at the 90 minute mark.)
- Cardiovascular Function - Change in Heart Rate Variability(Hydration Baseline Day 2)
- Cardiovascular Function - Change in Heart Rate Variability(Intervention Trial (Day 4) at the -90 minute mark)
- Cardiovascular Function - Change in Heart Rate Variability(Intervention Trial (Day 4) at the 0 minute mark)
- Cardiovascular Function - Change in Heart Rate Variability(Intervention Trial (Day 4) at the 30 minute mark)
- Cardiovascular Function - Change in Heart Rate Variability(Intervention Trial (Day 4) at the 90 minute mark)
- Cognitive Differences - Changes in Go/No Go Assessment(Intervention Trial (Day 4) at the -115 minute mark.)
- Cognitive Differences - Changes in Go/No Go Assessment(Intervention Trial (Day 4) at the 0 minute mark.)
- Cognitive Differences - Changes in Go/No Go Assessment(Intervention Trial (Day 4) at the 60 minute mark.)
- Cognitive Differences - Changes in Go/No Go Assessment(Intervention Trial (Day 4) at the 120 minute mark.)
- Cognitive Differences - Changes in 2 Choice Reaction Time(Intervention Trial (Day 4) at the -115 minute mark.)
- Cognitive Differences - Changes in 2 Choice Reaction Time(Intervention Trial (Day 4) at the 0 minute mark.)
- Cognitive Differences - Changes in 2 Choice Reaction Time(Intervention Trial (Day 4) at the 60 minute mark.)
- Cognitive Differences - Changes in 2 Choice Reaction Time(Intervention Trial (Day 4) at the 120 minute mark.)
- Cognitive Differences - Changes in Procedural Reaction Time(Intervention Trial (Day 4) at the -115 minute mark.)
- Cognitive Differences - Changes in Procedural Reaction Time(Intervention Trial (Day 4) at the 0 minute mark.)
- Cognitive Differences - Changes in Procedural Reaction Time(Intervention Trial (Day 4) at the 60 minute mark.)
- Cognitive Differences - Changes in Procedural Reaction Time(Intervention Trial (Day 4) at the 120 minute mark.)
- Cognitive Differences - Changes in Stroop Test(Intervention Trial (Day 4) at the -115 minute mark.)
- Cognitive Differences - Changes in Stroop Test(Intervention Trial (Day 4) at the 0 minute mark.)
- Cognitive Differences - Changes in Stroop Test(Intervention Trial (Day 4) at the 60 minute mark.)
- Cognitive Differences - Changes in Stroop Test(Intervention Trial (Day 4) at the 120 minute mark.)
- Perceptual Differences - Changes in Environmental Symptoms Questionnaire(Intervention Trial (Day 4) at the -115 minute mark.)
- Perceptual Differences - Changes in Environmental Symptoms Questionnaire(Intervention Trial (Day 4) at the 0 minute mark.)
- Perceptual Differences - Changes in Environmental Symptoms Questionnaire(Intervention Trial (Day 4) at the 60 minute mark.)
- Perceptual Differences - Changes in Environmental Symptoms Questionnaire(Intervention Trial (Day 4) at the 120 minute mark.)
- Perceptual Differences - Changes in Fatigue Scale(Intervention Trial (Day 4) at the -115 minute mark.)
- Perceptual Differences - Changes in Fatigue Scale(Intervention Trial (Day 4) at the 0 minute mark.)
- Perceptual Differences - Changes in Fatigue Scale(Intervention Trial (Day 4) at the 60 minute mark.)
- Perceptual Differences - Changes in Fatigue Scale(Intervention Trial (Day 4) at the 120 minute mark.)
- Perceptual Differences - Changes in Gastrointestinal Distress Scale(Intervention Trial (Day 4) at the -115 minute mark.)
- Perceptual Differences - Changes in Gastrointestinal Distress Scale(Intervention Trial (Day 4) at the 0 minute mark.)
- Perceptual Differences - Changes in Gastrointestinal Distress Scale(Intervention Trial (Day 4) at the 60 minute mark.)
- Perceptual Differences - Changes in Gastrointestinal Distress Scale(Intervention Trial (Day 4) at the 120 minute mark.)
- Perceptual Differences - Changes in Thermal Sensation Scale(Intervention Trial (Day 4) at the -115 minute mark.)
- Perceptual Differences - Changes in Thermal Sensation Scale(Intervention Trial (Day 4) at the 0 minute mark.)
- Perceptual Differences - Changes in Thermal Sensation Scale(Intervention Trial (Day 4) at the 60 minute mark.)
- Perceptual Differences - Changes in Thermal Sensation Scale(Intervention Trial (Day 4) at the 120 minute mark.)
- Perceptual Differences - Changes in Thirst Perception Scale(Hydration Baseline Day 1)
- Perceptual Differences - Changes in Thirst Perception Scale(Hydration Baseline Day 2)
- Perceptual Differences - Changes in Thirst Perception Scale(Hydration Baseline Day 3)
- Perceptual Differences - Changes in Thirst Perception Scale(Intervention Trial (Day 4) at the -115 minute mark.)
- Perceptual Differences - Changes in Thirst Perception Scale(Intervention Trial (Day 4) at the 0 minute mark.)
- Perceptual Differences - Changes in Thirst Perception Scale(Intervention Trial (Day 4) at the 60 minute mark.)
- Perceptual Differences - Changes in Thirst Perception Scale(Intervention Trial (Day 4) at the 120 minute mark.)
研究者
Douglas J Casa
Principal Investigator
University of Connecticut